Literature DB >> 1595456

Xe/CT cerebral blood flow evaluation of delayed symptomatic cerebral ischemia after subarachnoid hemorrhage.

M B Fukui1, D W Johnson, H Yonas, L Sekhar, R E Latchaw, S Pentheny.   

Abstract

PURPOSE: We examined the xenon/CT method of measuring cerebral blood flow in assessing the location, pattern of onset, and severity of delayed cerebral ischemia. PATIENTS AND METHODS: Fourteen patients with delayed neurologic deficits due to ischemia were selected from a group of 66 patients with subarachnoid hemorrhage. All blood flow studies were performed within 12 hours of deterioration and at regular intervals during medical management.
RESULTS: In 10 of the 14 patients, noncontrast CT did not identify a cause for deterioration, whereas the blood flow study revealed diminished flow values. Location of blood flow reduction was variable. In five of the 14 patients, blood flow reduction was closely related anatomically to the vessel of aneurysm origin. In another three, blood flow reduction was anatomically remote to the vessel of origin. The remaining six experienced local and remote cerebral blood flow reduction. Six of 14 patients suffered sudden, devastating deterioration, refractory to therapy and associated with blood flow of 15 cc/100 g.min or less, resulting in local or widespread infarction. The remaining eight had less severe blood flow reduction and did not infarct those territories.
CONCLUSIONS: Vasospasm can affect remote vessels as severely as local vessels and can affect remote vessels alone. Diminished cerebral blood flow correlated closely with clinical vasospasm in this group of patients. Xenon/CT cerebral blood flow studies can identify tissue at risk of infarction when CT is normal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595456      PMCID: PMC8331725     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  7 in total

Review 1.  CT perfusion cerebral blood flow imaging in neurological critical care.

Authors:  Mark R Harrigan; Jody Leonardo; Kevin J Gibbons; Lee R Guterman; L Nelson Hopkins
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  The impact of a highly visible display of cerebral perfusion pressure on outcome in individuals with cerebral aneurysms.

Authors:  Catherine J Kirkness; Robert L Burr; Kevin C Cain; David W Newell; Pamela H Mitchell
Journal:  Heart Lung       Date:  2008 May-Jun       Impact factor: 2.210

3.  Regional cerebral blood flow levels as measured by xenon-CT in vascular territorial low-density areas after subarachnoid hemorrhage are not always ischemic.

Authors:  E Fainardi; M F Tagliaferri; C Compagnone; A Tanfani; F Cocciolo; R Battaglia; M Frattarelli; R Pascarella; L Targa; A Chieregato
Journal:  Neuroradiology       Date:  2006-06-28       Impact factor: 2.804

4.  Persistent autoregulatory disturbance after angioplasty for cerebral vasospasm. A case report.

Authors:  D K Song; M R Harrigan; J P Deveikis; J E McGillicuddy
Journal:  Interv Neuroradiol       Date:  2004-10-20       Impact factor: 1.610

5.  Xenon-enhanced cerebral blood flow at 28% xenon provides uniquely safe access to quantitative, clinically useful cerebral blood flow information: a multicenter study.

Authors:  A P Carlson; A M Brown; E Zager; K Uchino; M P Marks; C Robertson; G P Sinson; A Marmarou; H Yonas
Journal:  AJNR Am J Neuroradiol       Date:  2011-06-23       Impact factor: 3.825

6.  Cortical blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage: three-dimensional N-isopropyl-p-[(123)I]iodoamphetamine single photon emission CT findings.

Authors:  Hiroki Ohkuma; Shigeharu Suzuki; Kanae Kudo; Shafiqul Islam; Tomonari Kikkawa
Journal:  AJNR Am J Neuroradiol       Date:  2003-03       Impact factor: 3.825

7.  Advanced imaging modalities in the detection of cerebral vasospasm.

Authors:  Jena N Mills; Vivek Mehta; Jonathan Russin; Arun P Amar; Anandh Rajamohan; William J Mack
Journal:  Neurol Res Int       Date:  2013-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.